Solid Biosciences (SLDB) Stock Price, News & Analysis

Company Overview

Solid Biosciences Inc. is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials.

Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.

Key Stats

• Today's Range: $6.86 to $7.29
• 50-Day Range: $5.61 to $8.63
• 52-Week Range: $2.41 to $8.87
• Volume: 2.26 million shs
• Average Volume: 963,952 shs
• Market Capitalization: $708.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.09
• Consensus Rating: Moderate Buy

Solid Biosciences Stock Analysis - MarketRank™

Solid Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 326th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Solid Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Solid Biosciences has a consensus price target of $16.09, representing about 123.5% upside from its current price of $7.20.

Amount of Analyst Coverage

Solid Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Solid Biosciences are expected to remain at ($1.59) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Solid Biosciences is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Solid Biosciences is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Solid Biosciences has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.78% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 9.38.

Change versus previous month

Short interest in Solid Biosciences has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solid Biosciences does not currently pay a dividend.

Dividend Growth

Solid Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Solid Biosciences this week, compared to 4 articles on an average week.

Search Interest

19 people have searched for SLDB on MarketBeat in the last 30 days. This is an increase of 111% compared to the previous 30 days.

MarketBeat Follows

4 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Solid Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,364.00 in company stock.

Percentage Held by Insiders

1.90% of the stock of Solid Biosciences is held by insiders.

Percentage Held by Institutions

81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLDB Stock Analysis - Frequently Asked Questions

How have SLDB shares performed this year?

Solid Biosciences' stock was trading at $5.64 at the start of the year. Since then, SLDB stock has increased by 27.7% and is now trading at $7.20.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) issued its quarterly earnings results on Thursday, March, 19th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01.

When did Solid Biosciences' stock split?

Solid Biosciences's stock reverse split on Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Solid Biosciences IPO?

Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Top institutional shareholders of Solid Biosciences include Bank of New York Mellon Corp (0.14%) and Hsbc Holdings PLC (0.04%). Insiders that own company stock include Perceptive Advisors Llc, Alexander Cumbo, David T Howton, Kevin Tan, Gabriel Brooks, Jessie Hanrahan, Paul Herzich, Ilan Ganot and Clare Kahn.
View institutional ownership trends.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 3/19/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLDB
• CIK: 1707502
• Web: www.solidbio.com
• Phone: (617) 337-4680
• Fax: N/A
• Employees: 100
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Solid Biosciences: $16.09
• High Price Target: $26.00
• Low Price Target: $9.00
• Potential Upside/Downside: +123.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$174.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -72.23%
• Return on Assets: -59.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.14
• Quick Ratio: 6.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.28 per share
• Price / Book: 3.16

Miscellaneous

• Outstanding Shares: 98,410,000
• Free Float: 96,543,000
• Market Cap: $708.55 million
• Optionable: Optionable
• Beta: 2.47